

A model for 2019-nCoV infection with treatment

Amar Nath Chatterjee¹ and Fahad Al Basir^{*2}

¹Department of Mathematics, K.L.S. College, Nawada, Magadh University, Bodh Gaya, Bihar-805110, India

²Department of Mathematics, Asansol Girls' College, Asansol-4, West Bebgal-713304, India

July 6, 2020

Abstract

The current emergence of coronavirus (2019-nCoV or **SARS-CoV-2**) puts the world in threat. The structural research on the receptor recognition by **SARS-CoV-2** has identified the key interactions between SARS-CoV-2 spike protein and its host (epithelium cell) receptor, also known as *angiotensin-converting enzyme 2 (ACE2)*. It controls both the cross-species and human-to-human transmissions of SARS-CoV-2. In view of this, we propose and analyze a mathematical model for investigating the effect of CTL responses over the viral mutation to control the viral infection when a post-infection **immunostimulant drug (Pidotimode)** is administered at regular intervals. Dynamics of the system with and without impulses have been analyzed using the basic reproduction number. This study shows that proper dosing interval and drug dose both are important to eradicate the viral infection.

Keywords: Mathematical model; Basic reproduction number; Stability analysis; Immunostimulant drug; Angiotensin Converting Enzyme 2 (ACE2); Impulsive differential equation.

1 Introduction

- ¹ A novel coronavirus named 2019-nCoV or **SARS-CoV-2** (an interim name
- ² **proposed by WHO (World Health Organization)** become pandemic since

*Corresponding author. Email: fahadalbasir@yahoo.com

3 December 2019. The first infectious respiratory syndrome was recognised in
4 Wuhan, Hubei province of China. Dedicated virologist identified and recog-
5 nised the virus within a short time [3]. The SARS-CoV-2 is a single standard
6 RNA virus genome which is closely related to severe acute respiratory syn-
7 drome SARS-CoV [4]. The infection of SARS-CoV-2 is associated with a
8 SARS-CoV like a disease with a fatality rate of 3.4% [5]. The World Health
9 Organisation (WHO) have named the disease as COVID-19 and declared it
10 as a public health emergency worldwide [2].

11 The common symptoms of COVID-19 are fever, fatigue, dry cough, myal-
12 gia. Also, some patients suffer from headaches, abdominal pain, diarrhea,
13 nausea, and vomiting. In the acute phase of infection, the disease may lead
14 to respiratory failure which leads to death also. From clinical observation,
15 within 1-2 days after patient symptoms, the patient becomes morbid after
16 4-6 days and the infection may clear within 18 days [6] depending on the
17 immune system. Thus appropriate quarantine measure for minimum two
18 weeks is taken by the public health authorities for inhibiting community
19 spread [1].

20 In [3], Zhou *et al.* identified that the respiratory tract as principal in-
21 fection site for COVID-19 infection. SARS-CoV-2 infects primary human
22 airway epithelial cells. Angiotensin converting enzyme II (ACE2) receptor
23 of epithelial cells plays an important role in cellular entry [3,8]. It has been
24 observed that ACE2 could be expressed in the oral cavity. ACE2 receptors
25 are higher in tongue than buccal and gingival tissues. These findings imply
26 that the mucosa of the oral cavity may be a potentially high-risk route of
27 COVID-19 infection. Thus epithelial cells of the tongue are the major routes
28 of entry for COVID-19. Zhou *et al.* [3] also reported that SARS-CoV-2 spikes
29 S bind with ACE2 receptor of epithelial cells with high affinity. The bonding
30 between S - spike of SARS-CoV-2 with ACE2 [8], results from the fusion
31 between the viral envelope and the target cell membrane and the epithelial
32 cells become infected. The S protein plays a major role in the induction of
33 protective immunity during the infection of SARS-CoV-2 by eliciting neu-
34 tralization antibody and T cell responses [10]. S protein is not only capable
35 of neutralizing antibody but it also contains several immunogenic T cell epi-
36 topes. Some of the epitopes found in either S1 or S2 domain. These proteins
37 are useful for SARS-CoV-2 drug development [14].

38 We know that virus clearance after acute infection is associated with
39 strong antibody responses. Antibody responses have the potential to control
40 the infection [15]. Also, CTL responses help to resolve infection and virus
41 persistence caused by weak CTL responses [9]. Antibody responses against
42 SARS-CoV-2 play an important role in preventing the viral entry process

43 [10]. Hsueh et al. [4] found that antibodies block viral entry by binding to the
44 S glycoprotein of SARS-CoV-2. To fight against the pathogen SARS-CoV-2,
45 the body requires SARS-CoV-2 specific $CD4^+T$ helper cells for developing
46 this specific antibody [10]. Antibody-mediated immunity protection helps
47 the anti-SARS-CoV serum to neutralize COVID-19 infection. Besides that,
48 the role of T cell responses in COVID-19 infection is very much important.
49 Cytotoxic T lymphocytes (CTLs) responses are important for recognizing
50 and killing infected cells, particularly in the lungs [10]. But the kinetic of
51 the CTL responses and antibody responses during SARS-CoV-2 infection is
52 yet to be explored. Our study will focus on the role of CTL and its possible
53 implication on treatment and drug development. the drug that stimulates
54 the CTL responses represents the best hope for control of COVID-19. Here
55 we have modeled the situation where CTLs can effectively control the viral
56 infection when the post-infection drug is administered at regular intervals.

57 Mathematical modeling with real data can help in predicting the dynam-
58 ics and control of an infectious disease [32,33]. A four-dimensional dynamical
59 model for a viral infection is proposed by Tang et al. [11] for MERS-CoV
60 mediated by DPP4 receptors. In case of SARS-CoV-2, the infection pro-
61 cess is almost similar with MERS-CoV and SARS-CoV. For SARS-CoV-2
62 infection, the ACE2 receptor of epithelium cell are the major target area.

63 Since the dynamics of the disease transmission of SARS-CoV-2 in cellular
64 level is yet to be explored, thus we investigate the system in the light of
65 previous literature of [11,26–29] to formulate the dynamic model which play
66 a significant role in describing the interaction between uninfected cells, free
67 virus and CTL responses. We propose a novel deterministic model which
68 describes the cell biological infection of SARS-CoV-2 with epithelial cells
69 and the role of the ACE2 receptor.

70 We explained the dynamics in the acute infection stage. It has been
71 observed that CTL proliferate and differentiate antibody production after
72 they encounter antigen. Here we investigate the effect of CTL responses
73 over the viral mutation to control viral infection when a post-infection drug
74 is administered at regular intervals by mathematical perspective.

75 It is clinically evident that immunostimulants play a crucial role in the
76 case of respiratory disease. Among the currently available immunostimu-
77 lants, Pidotimod is the most effective for the respiratory disease [31]. Pido-
78 timod increases the level of immunoglobulins (IgA, IgM, IgG) and activates
79 the CTL responses to fight against the disease.

80 In this article, we have considered the infection dynamics of SARS-CoV-
81 2 infection in the acute stage. We have used impulsive differential equations
82 to study the immunostimulant drug dynamics and the effects of perfect

83 drug adherence. In recent years the effects of perfect adherence have been
84 studied by using impulsive differential equations in [12, 13, 17–21]. With
85 the help of impulsive differential equations, the effect of maximal acceptable
86 drug holidays and optimal dosage can be found more precisely [12, 21].

87 The article is organised as follows: The very next section contains the
88 formulation of the impulsive mathematical model. Dynamics of the system
89 without impulses has been provided in section 3. The system with impulses
90 has been analysed in section 4. Numerical simulations, on the basis of the
91 outcomes of section 3 and 4, have been included in section 5. Discussion in
92 section 6 concludes the paper.

93 2 Model formulation

94 As discussed in the previous section, we propose a model considering the
95 interaction between epithelium cells and SARS-CoV-2 virus along with lytic
96 CTL responses over the infected cells. We consider five populations namely
97 the uninfected epithelium cells $T(t)$, infected cells $I(t)$, ACE2 receptor of
98 the epithelial cells $E(t)$ and CTLs against the pathogen $C(t)$.

99 In this model, we consider which represents the concentration of ACE2
100 on the surface of uninfected cells, which can be recognized by surface spike
101 (S) protein of SARS-CoV-2 [24].

102 It is assumed that the susceptible cells are produced at a rate λ_1 from the
103 precursor cells and die at a rate d_T . The susceptible cells become infected a
104 rate $\beta E(t)V(t)T(t)$. The constant d_I is the death rate of the infected cells.
105 Infected cells are also cleared by the body's defensive CTLs at a rate p .

106 The infected cells produce new viruses at the rate md_I during their life,
107 and d_V is the death rate of new virions, where m is any positive integer. It
108 is also assumed that ACE2 is produced from the surface of uninfected cells
109 at the constant rate λ_2 and the ACE2 is destroyed, when free viruses try to
110 infect uninfected cells, at the rate $\theta\beta E(t)V(t)T(t)$ and is hydrolyzed at the
111 rate $d_E E$.

112 CTL proliferation in the presence of infected cells is described by the
113 term

$$\alpha IC \left(1 - \frac{C}{C_{max}} \right),$$

114 which shows the antigen dependent proliferation. Here we consider the lo-
115 gistic growth of CTL with C_{max} as the maximum concentration of CTL and
116 d_c is its rate of decay.

117 With the above assumptions, we have the following mathematical model
 118 characterising the SARS-CoV-2 dynamics:

$$\begin{aligned}
 \frac{dT}{dt} &= \lambda_1 - \beta EVT - d_T T, \\
 \frac{dI}{dt} &= \beta EVT - d_I I - pIC, \\
 \frac{dV}{dt} &= md_I I - d_V V, \\
 \frac{dE}{dt} &= \lambda_2 - \theta \beta EVT - d_E E, \\
 \frac{dC}{dt} &= \alpha Y C \left(1 - \frac{C}{C_{max}} \right) - d_c C.
 \end{aligned} \tag{1}$$

119 We now modify the above model incorporating pulse periodic drug dosing
 120 using impulsive differential equation [22, 23].

121 We consider the perfect adherence behaviour of immunostimulant drug
 122 for SARS-CoV-2 infected patients at fixed drug dosing times t_k , $k \in \mathbb{N}$.

123 We assume that CTL cells increases by a fixed amount ω , which is pro-
 124 portional to the total number of CTLs that the drug can stimulate. Thus
 125 the above model takes the following form:

$$\begin{aligned}
 \frac{dT}{dt} &= \lambda_1 - \beta EVT - d_T T, \\
 \frac{dI}{dt} &= \beta EVT - d_I I - pIC, \\
 \frac{dV}{dt} &= md_I I - d_V V, \\
 \frac{dE}{dt} &= \lambda_2 - \theta \beta EVT - d_E E, \\
 \frac{dC}{dt} &= \alpha Y C \left(1 - \frac{C}{C_{max}} \right) - d_c C, & t \neq t_k, \\
 C(t_k^+) &= \omega + C(t_k^-), & t = t_k.
 \end{aligned} \tag{2}$$

126 Here, $C(t_k^-)$ denotes the CTL cells concentration immediately before the
 127 impulse, $C(t_k^+)$ denotes the concentration after the impulse and ω is the
 128 fixed amount which is proportional to the total number of CTLs the drug
 129 stimulates at each impulse time t_k , $k \in \mathbb{N}$.

130 **Remark 1.** *It can be noted that when there is no drug application in the*
 131 *system, model (2) becomes model (1).*

132 3 Analysis of the system without drug

133 In this section, we analyse the dynamics of the system without impulses i.e.
 134 system (1). We have derived the *basic reproduction number* for the system.
 135 Stability of equilibria are discussed using the number.

136 3.1 Existence of equilibria

137 Model (2) has three steady states namely (i) the disease-free equilibrium
 138 $E_1 \left(\frac{\lambda_1}{d_T}, 0, 0, \frac{\lambda_2}{d_E}, 0 \right)$, (ii) with $\bar{E} > \frac{d_T d_V}{\beta \lambda_1 m}$, there is a CTL-responses-free equi-
 139 librium, $E_2(\bar{T}, \bar{I}, \bar{V}, \bar{E}, 0)$, where,

$$\begin{aligned} \bar{T} &= \frac{d_V}{\beta m \bar{E}}, & \bar{I} &= \frac{\beta \lambda_1 n \bar{E} - d_T d_V}{\beta d_I m \bar{E}}, & \bar{V} &= \frac{\beta \lambda_1 m \bar{E} - d_T d_V}{\beta d_V \bar{E}}, \\ \bar{E} &= \frac{-(\theta \beta \lambda_1 m - \beta \lambda_2 m) + \sqrt{(\theta \beta \lambda_1 m - \beta \lambda_2 m)^2 + 4 \beta m d_T d_V d_E \theta}}{2 \beta d_E m}, \end{aligned}$$

140 and (iii) the endemic equilibrium E^* which is given by

$$\begin{aligned} T^* &= \frac{\lambda_1 \alpha - d_I \alpha I^* - p d_c}{d_T \alpha}, \\ V^* &= \frac{d_I m I^*}{d_V}, & E^* &= \frac{\lambda_2 \alpha - \theta \alpha d_I I^* - \theta p d_c}{d_E \alpha}, \\ C^* &= \frac{(\alpha I^* - d_c) C_{max}}{\alpha I^*}. \end{aligned}$$

141 where, I^* is the positive root of the cubic equation

$$L_0 I^3 + L_1 I^2 + L_2 I + L_3 = 0, \quad (3)$$

142 with,

$$\begin{aligned} L_0 &= -\alpha^2 \theta \beta d_I^3 m, \\ L_1 &= -2 \alpha \theta \beta d_I^2 d_c m p + \alpha^2 \theta \beta d_I^2 \lambda_1 m + \alpha^2 \beta d_I^2 \lambda_2 m, \\ L_2 &= \alpha^2 d_T d_I d_V d_E + \alpha \theta \beta d_I d_c \lambda_1 m p + \alpha \beta d_I d_c \lambda_2 m p \\ &\quad - \alpha^2 \beta d_I \lambda_1 \lambda_2 m - \theta \beta d_I d_c^2 m p^2, \\ L_3 &= \alpha d_T d_V d_E d_c p. \end{aligned}$$

143 **Remark 2.** Note that $L_0 < 0$ and $L_3 > 0$. Thus, the equation (3) has at
 144 least one positive real root. If $L_1 > 0$ and $L_2 < 0$, then (3) can have two
 145 positive roots. For a feasible endemic equilibrium we also need

$$\min \left\{ \frac{\lambda_1 \alpha - p d_c}{d_I \alpha}, \frac{\lambda_2 \alpha - \theta p d_c}{\theta \alpha d_I} \right\} > I^* > \frac{d_c}{\alpha}.$$

146 3.2 Stability of equilibria

147 In this section, the characteristic equation at any equilibria is determined
 148 for the local stability of the system (2). Linearizing the system (2) at any
 149 equilibria $E(T, I, V, E, C)$ yields the characteristic equation

$$\Delta(\xi) = |\xi I_n - \mathbf{A}| = 0,$$

150 where I_n is the identity matrix and $\mathbf{A} = [a_{ij}]$ is the following 5×5 matrix
 151 given by

$$\mathbf{A} = \begin{bmatrix} -\beta EV - d_T & 0 & -\beta ET & -\beta VT & 0 \\ \beta EV & -d_I - pC & \beta ET & \beta VT & -pI \\ 0 & d_I m & -d_v & 0 & 0 \\ -\theta \beta EV & 0 & -\theta \beta ET & -\theta \beta VT - d_E & 0 \\ 0 & \alpha C \left(1 - \frac{C}{C_{max}}\right) & 0 & 0 & a_{55} \end{bmatrix},$$

152 with $a_{55} = \alpha I \left(1 - \frac{2C}{C_{max}}\right) - d_c$. We finally get the characteristic equation as

$$\psi(\xi) = \xi^5 + A_1 \xi^4 + A_2 \xi^3 + A_3 \xi^2 + A_4 \xi + A_5 = 0. \quad (4)$$

153 The coefficients A_i , $i = 1, 2, \dots, 5$ are given in **Appendix-A**.

154 Looking at stability of any equilibrium E , the Routh-Hurwitz criterion
 155 gives that all roots of this characteristic equation (4) have negative real
 156 parts, provided the following conditions hold

$$\begin{aligned} A_5 > 0, \quad A_1 A_2 - A_3 > 0, \quad A_3(A_1 A_2 - A_3) - A_1(A_1 A_4 - A_5) > 0, \\ (A_1 A_2 - A_3)(A_3 A_4 - A_2 A_5) - (A_1 A_4 - A_5)^2 > 0. \end{aligned} \quad (5)$$

157 Let us define the *basic reproduction number* as

$$R_0 = \frac{m\beta\lambda_1\lambda_2}{d_T d_E d_V}, \quad (6)$$

158 then using (5) we can derived the following result:

159 **Theorem 1.** *Disease-free equilibrium $E_1 \left(\frac{\lambda_1}{d_T}, 0, 0, \frac{\lambda_2}{d_E}, 0\right)$ of the model (2)*
 160 *is stable for $R_0 < 1$, and unstable for $R_0 > 1$.*

161 At E_2 one eigenvalue is $-d_c$ and rest of the eigenvalues satisfy the fol-
 162 lowing equation

$$\xi^4 + B_1\xi^3 + B_2\xi^2 + B_3\xi + B_4 = 0$$

163 The coefficients B_i , $i = 1, 2, \dots, 5$ are given in **Appendix-B**.

164 Using Routh-Hurwitz criterion, we have the following theorem.

165 **Theorem 2.** *CTL-free equilibrium, $E_2(\bar{T}, \bar{I}, \bar{V}, \bar{E}, 0)$, is asymptotically sta-*
 166 *ble if and only if the following conditions are satisfied*

$$\begin{aligned} B_1 > 0, \quad B_2 > 0, \quad B_3 > 0, \quad B_4 > 0, \\ B_1B_2 - B_3 > 0, \quad (B_1B_2 - B_3)B_3 - B_1^2B_4 > 0. \end{aligned} \quad (7)$$

167 Denoting $A_i^* = A_i(E^*)$ and using (5), we have the following theorem
 168 establishing the stability of coexisting equilibrium E^* .

169 **Theorem 3.** *The coexisting equilibrium E^* is asymptotically stable if and*
 170 *only if the following conditions are satisfied*

$$\begin{aligned} A_5^* > 0, \quad A_1^*A_2^* - A_3^* > 0, \quad A_3^*(A_1^*A_2^* - A_3^*) - A_1^*(A_1^*A_4^* - A_5^*) > 0, \\ (A_1^*A_2^* - A_3^*)(A_3^*A_4^* - A_2^*A_5^*) - (A_1^*A_4^* - A_5^*)^2 > 0. \end{aligned} \quad (8)$$

171 4 Dynamics of the system with impulsive drug 172 dosing

173 In this section we consider the model system (2). Before analysing the
 174 system, we first discuss the one dimensional impulse system as follows:

$$\begin{aligned} \frac{dC}{dt} &= \alpha IC \left(1 - \frac{C}{C_{max}}\right) - d_c C, \quad t \neq t_k. \\ C(t_k^+) &= \omega + C(t_k^-), \quad t = t_k. \end{aligned} \quad (9)$$

175 $C(t_k^-)$ denotes the CTL responses immediately before the impulse drug dos-
 176 ing, $C(t_k^+)$ denotes the concentration after the impulse and ω is the dose
 177 that is taken at each impulse time t_k , $k \in \mathbb{N}$.

178 We now consider the following linear system,

$$\begin{aligned} \frac{dC}{dt} &= -d_c C, \quad t \neq t_k \\ \Delta C &= \omega, \quad t = t_k \end{aligned} \quad (10)$$

179 where, $\Delta = C(t_k^+) - C(t_k^-)$. Let $\tau = t_{k+1} - t_k$ be the period of the campaign.
 180 The solution of the system (10) is,

$$C(t) = C(t_k^+)e^{-d_c(t-t_k)}, \quad \text{for } t_k < t \leq t_{k+1}. \quad (11)$$

181 In presence of impulsive dosing, we can get the recursion relation at the
 182 moments of impulse as,

$$C(t_k^+) = C(t_k^-) + \omega.$$

Thus the amount of CTL before and after the impulse is obtained as,

$$C(t_k^+) = \frac{\omega(1 - e^{-k\tau d_c})}{1 - e^{-\tau d_c}}$$

and

$$C(t_{k+1}^-) = \frac{\omega(1 - e^{-k\tau d_c})e^{-\tau d_c}}{1 - e^{-\tau d_c}}.$$

183 Thus the limiting case of the CTL amount before and after one cycle is
 184 as follows:

$$\lim_{k \rightarrow \infty} C(t_k^+) = \frac{\omega}{1 - e^{-\tau d_c}} \quad \text{and} \quad \lim_{k \rightarrow \infty} C(t_{k+1}^-) = \frac{\omega e^{-\tau d_c}}{1 - e^{-\tau d_c}}$$

185 and

$$C(t_{k+1}^+) = \frac{\omega e^{-\tau d_c}}{1 - e^{-\tau d_c}} + \omega = \frac{\omega}{1 - e^{-\tau d_c}}.$$

186 **Definition 1.** Let $\Lambda \equiv (S_u, S_a, I, C)$, $B_0 = [B : R_+^4 \rightarrow R_+]$, then we say
 187 that B belong to class B_0 if the following conditions hold:

- 188 (i) B is continuous on $(t_k, t_{k+1}] \times R_+^3$, $n \in N$ and for all $\Lambda \in R^4$,
 189 $\lim_{(t, \mu) \rightarrow (t_k^+, \Lambda)} B(t, \mu) = B(t_k^+, \Lambda)$ exists,
 190 (ii) B is locally Lipschitzian in Λ .

191 We now recall some results for our analysis from [22, 23].

192 **Lemma 1.** Let $Z(t)$ be a solution of the system (9) with $Z(0^+) \geq 0$. Then
 193 $Z_i(t) \geq 0$, $i = 1, \dots, 4$ for all $t \geq 0$. Coreover, $Z_i(t) > 0$, $i = 1, \dots, 4$ for all
 194 $t > 0$ if $Z_i(0^+) > 0$, $i = 1, \dots, 4$.

195 **Lemma 2.** There exists a constant γ such that $T(t) \leq \gamma$, $I(t) \leq \gamma$, $V(t) \leq \gamma$
 196 $E(t) \leq \gamma$ and $C(t) \leq \gamma$ for each and every solution $Z(t)$ of system (9) for
 197 all sufficiently large t .

198 **Lemma 3.** *Let $B \in B_0$ and also consider that*

$$\begin{aligned} D^+B(t, Z) &\leq j(t, B(t, Z(t))), \quad t \neq t_k, \\ B(t, Z(t^+)) &\leq \Phi_n(B(t, Z(t))), \quad t = t_k, \end{aligned}$$

199 *where $j : \mathbf{R}_+ \times \mathbf{R}_+ \rightarrow \mathbf{R}$ is continuous in $(t_k, t_{k+1}]$ for $e \in \mathbf{R}_+^2$, $n \in N$,*
 200 *the limit $\lim_{(t,V) \rightarrow (t_k^+, x)} j(t, g) = j(t_k^+, x)$ exists and $\Phi_n^i (i = 1, 2) : \mathbf{R}_+ \rightarrow \mathbf{R}_+$*
 201 *is non-decreasing. Let $y(t)$ be a maximal solution of the following impulsive*
 202 *differential equation*

$$\begin{aligned} \frac{dx(t)}{dt} &= j(t, x(t)), \quad t \neq t_k, \\ x(t^+) &= \Phi_n(x(t)), \quad t = t_k, \quad x(0^+) = x_0, \end{aligned} \tag{12}$$

203 *existing on $(0^+, \infty)$. Then $B(0^+, Z_0) \leq x_0$ implies that $B(t, Z(t)) \leq y(t)$, $t \geq$*
 204 *0, for any solution $Z(t)$ of system (9). If j satisfies additional smoothness*
 205 *conditions to ensure the existence and uniqueness of solutions for (12), then*
 206 *$y(t)$ is the unique solution of (12).*

207 We now consider the following sub-system:

$$\frac{dC(t)}{dt} = -d_c C, \quad t \neq t_k, \quad C(t_k^+) = C(t_k) + \omega, \quad C(0^+) = C_0. \tag{13}$$

208 The Lemma provided above, gives the following result,

Lemma 4. *System (13) has a unique positive periodic solution $\tilde{C}(t)$ with period τ and given by*

$$\tilde{C}(t) = \frac{\omega \exp(-d_c(t - t_k))}{1 - \exp(-\tau d_c)}, \quad t_k \leq t \leq t_{k+1}, \quad \tilde{C}(0^+) = \frac{d_c}{1 - \exp(-\tau d_c)}.$$

209 We use this result to derive the following theorem.

210 **Theorem 4.** *The disease-free periodic orbit $(\tilde{T}, 0, 0, \tilde{E}, \tilde{C})$ of the system (2)*
 211 *is locally asymptotically stable if*

$$\tilde{R}_0 < 1 \tag{14}$$

212 *where,*

$$\tilde{R}_0 = \frac{md_I\beta}{d_T d_E d_V \tau} \int_0^\tau \frac{\tilde{T}\tilde{E}}{d_I + p\tilde{C}} dt.$$

Proof. Let the solution of the system (9) without infected people be denoted by $(\tilde{T}, 0, 0, \tilde{E}, \tilde{C})$, where

$$\tilde{C}(t) = \frac{\omega \exp(-d_c(t - t_k))}{1 - \exp(-\tau d_c)}, \quad t_k \leq t \leq t_{k+1},$$

with initial condition $C(0^+)$ as in Lemma 4. We now test the stability of the equilibria. The variational matrix at $(\tilde{T}, 0, 0, \tilde{E}, \tilde{C})$ is given by

$$M(t) = [m_{ij}] = \begin{pmatrix} -d_T & 0 & m_{13} & 0 & 0 \\ 0 & -(d_I + p\tilde{C}) & \beta\tilde{E}\tilde{T} & 0 & 0 \\ 0 & md_I & -d_v & 0 & 0 \\ 0 & 0 & m_{43} & -d_E & 0 \\ 0 & m_{52} & 0 & 0 & -d_c \end{pmatrix}.$$

The monodromy matrix \mathbb{P} of the variational matrix $M(t)$ is

$$\mathbb{P}(\tau) = I_n \exp\left(\int_0^\tau M(t)dt\right),$$

213 where I_n is the identity matrix. Note that m_{13}, m_{43}, m_{52} are not required
214 for this analysis, therefore we have not mentioned their expressions.

215 We can write $\mathbb{P}(\tau) = \text{diag}(\sigma_1, \sigma_2, \sigma_3, \sigma_4, \sigma_5)$, where, σ_i , $i = 1, 2, 3, 4, 5$,
216 are the Floquet multipliers and they are determined as

$$\begin{aligned} \sigma_1 &= \exp(-d_T\tau), \quad \sigma_{2,3} = \exp\left(\int_0^\tau \frac{1}{2} \left[-A \pm \sqrt{A^2 - 4B}\right] dt\right), \\ \sigma_4 &= \exp(-d_E\tau), \quad \sigma_5 = \exp(-d_c\tau). \end{aligned}$$

217 Here $A = d_I + d_V + p\tilde{C}$ and $B = d_V(d_I + p\tilde{C}) - md_I\beta\tilde{E}\tilde{T}$. Clearly $\lambda_{1,4,5} < 1$.
218 It is easy to check that $A^2 - 4B > 0$ and if $B \geq 0$ and hold then we
219 have $\lambda_{2,3} < 1$. Thus, according to Floquet theory, the periodic solution
220 $(\tilde{S}_u(t), 0, 0, \tilde{M}(t))$ of the system (9) is locally asymptotically stable if the
221 conditions given in (14) hold. \square

Table 1: Set of parameter values used of numerical simulations.

| Parameter | Explanation | Assigned value |
|-------------|---------------------------------------|----------------|
| λ_1 | Production rate of uninfected cell | 5 |
| λ_2 | Production rate of ACE2 | 1 |
| β | Disease transmission rate | 0.0001 |
| θ | Bonding rate of ACE2 | 0.3 |
| d_T | Death rate of uninfected cells | 0.1 |
| d_I | death rate of infected cells | 0.1 |
| d_V | Removal rate of virus | 0.1 |
| d_E | Hydrolysing rate of epithelium cells | 0.1 |
| d_C | decay rate of CTL | 0.1 |
| p | Killing rate of infected cells by CTL | 0.01 |
| m | Number of new virions produced | 10-100 |
| α | Proliferation rate of CTL | 0.22 |
| C_{max} | Maximum proliferation of CTL | 100 |

222 5 Numerical results and discussion

223 In this section, we have observed the dynamical behaviours of system with-
 224 out drug (Figure 1 and Figure 2) and with impulsive effect of the drug dose
 225 (Figure 3 and Figure 4) through numerical simulations taking the paramete-
 226 rs mainly from [11, 30, 31].

227 We have mainly focused on the role of CTL and its possible implication
 228 on the treatment and drug development. The drug that stimulates the
 229 CTL responses represents the best hope for control of COVID-19. Here we
 230 have determined the situation where CTLs can effectively control the viral
 231 infection when the post-infection drug is administered at regular intervals.

232 Existence of equilibria of the system without drug dose is shown for
 233 different values of basic reproduction number R_0 . In plotting the Figure 1,
 234 we have varied the value of infection rate β . It is observed that for lower
 235 infection rate (that corresponds to $R_0 < 1$) disease free equilibrium E_1 is
 236 stable (corroborated with Theorem 1). It becomes unstable and ensure the
 237 existence of CTL-free equilibrium E_2 which is stable if $R_0 < 2.957$ (which
 238 corresponds to $\beta = 0.00005963$) and unstable otherwise. (This satisfies
 239 Theorem 2). Again we see that when E_2 is unstable the E^* is feasible. Also
 240 whenever E^* exists, it is stable which verified the Theorem 3.

241 Effect of immune response rate α is plotted in Figure 2. We observe that
 242 in the absence of Drug , the CTL count and ACE2 increases with increasing
 243 value of α . Steady state value of infected cell I^* and virus V^* decreases




Figure 1: Existence and stability of equilibria is shown with respect to R_0 . Parameters values used in this figure are taken from Table 1 and $m = 10$. We have varied the value of β in (0.00001, 0.0001).




Figure 2: In the absence of the drug, effect of growth rate of CTL i.e. α on the steady state values of model population is shown. Parameters values used in this figure are same as Figure 1 except α .




Figure 3: Numerical solution of the model system with and without drug dose is shown taking parameters as in Figure 1. In this figure, $\tau = 2$, $\omega = 50$.

244 significantly as α increases.

245 Due to the impulsive nature of the drugs, there are no equilibria of the
 246 system i.e. population do not reach to towards equilibrium point, rather ap-
 247 proach a periodic orbit. Hence, we evaluate equilibrium-like periodic orbits.
 248 There are two periodic orbits of the system (2) namely the disease-free pe-
 249 riodic orbit and endemic periodic orbit. Here our aim is to find the stability
 250 of disease-free periodic orbit.

251 Figure 3 compare the system without and with impulse Drug effect. In
 252 the absence of Drug we observe that the CTL count approaches a stable
 253 equilibrium. Under regular drug dosing, the CTL count oscillates in an im-
 254 pulsive periodic orbit. Assuming perfect adherence, if the drug is sufficiently
 255 strong, both infected cell and virus population are approaches towards ex-
 256 tinction. In this case, the total number of uninfected cells reach its maxi-
 257 mum level which implies that the system approaches towards its infection
 258 free state (Theorem 4).

259 If we take sufficiently large impulsive interval $\tau = 5$ days (keeping rate
 260 $\omega = 50$ fixed, as in Figure 3) or lower dosage effect $\omega = 20$ (keeping interval
 261 $\tau = 2$ fixed, as in Figure 3), in both the cases, infection is remains present




Figure 4: Numerical solution of the model system for different rates of Drug dosing and different intervals of impulses.

262 in the system. Thus proper dosage of drug and optimal dosing interval are
 263 important for infection management.

264 6 Conclusion

265 In this article, the role of **immunostimulant drug (mainly Pidotimod)** during
 266 interactions between SARS-CoV-2 spike protein and **epithelial cell** receptor
 267 ACE2 in COVID-19 infection has been studied as a possible **drug dosing**
 268 policy. To reactivate the CTL responses during the acute infection period,
 269 **immune activator drugs** is delivered to the host system in an impulsive mode.

270 The **immunostimulant drug** when administered, the best possible CTL
 271 responses can act against the infected or virus-producing cells to neutralize
 272 infection. This particular situation can keep the infected cell population at
 273 a very low level. In the proposed mathematical model, we have analyzed
 274 the optimal dosing regimen for which infection can be controlled.

275 From this study, it has been observed that when the basic reproduction
 276 ratio lies below one, we expect the system to attain its disease-free state.
 277 However, the system switches from disease-free state to CTL-free equilib-
 278 rium state when $1 < R_0 < 2.957$. If $R_0 > 2.957$, the CTL-free equilibrium

279 moves to an endemic state (Figure 1).

280 Here we have explored the immunostimulant drug dynamics by the help
281 of impulsive differential equations. With the help of impulsive differential
282 equations, we have studied how the effect of maximal acceptable optimal
283 dosage can be found more precisely. Impulsive system shows that proper
284 dosage and dosing intervals are important for the eradication of the infected
285 cells and virus population which results the control of pandemic (Figure 3).

286 It has also been observed that the length of the dosing interval and the
287 drug dose play a very decisive role to control and eradicate the infection.
288 The most interesting prediction of this model is that effective therapy can
289 often be achieved, even for low adherence, if the dosing regimen is adjusted
290 appropriately (Figure 4). Also if the treatment regimen is not adjusted
291 properly, the therapy is not effective at all. This approach might also be
292 applicable to a combination of antiviral therapy.

293 Future extension work of the combination of drug therapy should also
294 include more realistic patterns of non-adherence (random drug holidays, im-
295 perfect timing of successive doses), more accurate intracellular pharmaco-
296 kinetics and leads towards better estimates of drug dosage and drug dosing
297 intervals.

298 We end the paper with the quotation: *“This outbreak is a test of political,*
299 *financial and scientific solidarity for the world to fight a common enemy that*
300 *does not respect borders..., what matters now is stopping the outbreak and*
301 *saving lives.”* by Dr. Tedros, Director General, WHO [25].

302 **Data Availability**

303 The data used for supporting the findings are included within the article.

304 **Conflict of interest**

305 The authors declare that there is no conflict of interest.

306 **Authors Contributions**

307 Both authors contributed equally to this work.

308 References

- 309 [1] World Health Organization, (2020). Considerations for quarantine
310 of individuals in the context of containment for coronavirus disease
311 (COVID-19): interim guidance, 29 February 2020.
- 312 [2] World Health Organization, 2020. WHO Director-General's opening
313 remarks at the media briefing on COVID-19-11 March 2020. Geneva,
314 Switzerland.
- 315 [3] Zhou, P. et al. (2020). A pneumonia outbreak associated with a new
316 coronavirus of probable bat origin. *Nature*. Published online February
317 3, 2020. [https://doi.org/ 10.1038/s41586-020-2012-7](https://doi.org/10.1038/s41586-020-2012-7).
- 318 [4] Hsueh PR, Huang LM, Chen PJ, Kao CL, Yang P.C. (2004). Chrono-
319 logical evolution of IgM, IgA, IgG and neutralisation antibodies after
320 infection with SARS-associated coronavirus. *Clin Microbiol Infect*, 10,
321 1062-1066.
- 322 [5] Zhu, N. et al. (2020). A novel coronavirus from patients with pneumonia
323 in China, *N. Engl. J. Med.* 382, 2019, 727-733.
- 324 [6] Zou, L. et al. (2020). SARS-CoV-2 viral load in upper respiratory spec-
325 imens of infected patients. *N. Engl. J. Med.* Published online February
326 19, 2020.
- 327 [7] Xu H., Zhong L., Deng J., Peng J., Dan H., Zeng X., Li T., Chen
328 Q., (2020). High expression of ACE2 receptor of 2019-nCoV on the
329 epithelial cells of oral mucosa, *International Journal of Oral Science*,
330 12:8.
- 331 [8] Wan, Y., Shang, J., Graham, R., Baric, R.S. and Li, F., (2020). Re-
332 ceptor recognition by the novel coronavirus from Wuhan: an analysis
333 based on decade-long structural studies of SARS coronavirus. *Journal*
334 *of virology*, 94(7).
- 335 [9] Zheng, M., Gao, Y., Wang, G., Song, G., Liu, S., Sun, D., Tian, Z.
336 (2020). Functional exhaustion of antiviral lymphocytes in COVID-19
337 patients. *Cellular & molecular immunology*, 17(5), 533-535.
- 338 [10] Hsueh-Ling Janice Oh, Samuel Ken-En Gan, Antonio Bertoletti, Yee-
339 Joo Tan, Understanding the T cell immune response in SARS coro-
340 navirus infection, *Emerging Microbes and Infections* (2012) 1, e23;
341 [doi:10.1038/emi.2012.26](https://doi.org/10.1038/emi.2012.26).

- 342 [11] Tang S., Ma W., Bai P., (2017). A Novel Dynamic Model Describing the
343 Spread of the MERS-CoV and the Expression of Dipeptidyl Peptidase
344 4 Computational and Mathematical Methods in Medicine, Article ID
345 5285810.
- 346 [12] Miron R.E., Smith R.J. (2010). Modelling imperfect adherence to HIV
347 induction therapy. *BMC Infect Dis* 10: 6.
- 348 [13] Lou J, Smith R.J. Modelling the effects of adherence to the HIV fusion
349 inhibitor enfuvirtide. *J Theor Biol* 2011; 268: 1–13.
- 350 [14] Li, G. and De Clercq, E., 2020. Therapeutic options for the 2019 novel
351 coronavirus (2019-nCoV).
- 352 [15] Rothan, H.A. and Byrareddy, S.N., 2020. The epidemiology and patho-
353 genesis of coronavirus disease (COVID-19) outbreak. *Journal of Au-
354 toimmunity*, p.102433.
- 355 [16] Chen J, Hu C, Chen L, Tang L, Zhu Y, Xu X, Chen L, Gao H, Lu X,
356 Yu L, Dai X. Clinical study of mesenchymal stem cell treating acute
357 respiratory distress syndrome induced by epidemic Influenza A (H7N9)
358 infection, a hint for COVID-19 treatment. *Engineering*. 2020 Feb 28.
- 359 [17] Smith RJ, Aggarwala BD. Can the viral reservoir of latently infected
360 CD4(+) T cells be eradicated with antiretroviral HIV drugs? *J Math
361 Biol* 2009; 59: 697–715.
- 362 [18] Smith R.J. (2008). Explicitly accounting for antiretroviral drug uptake
363 in theoretical HIV models predicts long-term failure of protease-only
364 therapy. *J Theor Biol* 251, 227-237.
- 365 [19] Smith R.J., Wahl LM. Drug resistance in an immunological model of
366 HIV-1 infection with impulsive drug effects. *Bull Math Biol* 2005; 67:
367 783–813.
- 368 [20] Lou J., Chen L., Ruggeri T. (2009). An Impulsive Differential Model on
369 Post Exposure Prophylaxis to HIV-1 Exposed Individual. *J Biol Syst.*
370 17, 659–683.
- 371 [21] Roy P. K., Chatterjee A. N., Li X. Z., (2016). The effect of vaccination
372 to dendritic cell and immune cell interaction in HIV disease progression.
373 *International Journal of Biomathematics*, 9 (1), p.1650005.

- 374 [22] Yu H., Zhong S., Agarwal R. P., (2011). Mathematics analysis and chaos
375 in an ecological model with an impulsive control strategy, *Communica-*
376 *tions in Nonlinear Science and Numerical Simulation*, 16(2), 776-786.
- 377 [23] Lakshmikantham V., Bainov D. D., Simeonov P. S., *Theory of Impulsive*
378 *Differential Equations*, Series in Modern Applied Mathematics, World
379 Scientific Publishing, 6, (1989).
- 380 [24] Qing E., Gallagher T. (2020). SARS Coronavirus Redux. *Trends in*
381 *Immunology*. Mar 12, 2020.
- 382 [25] World Health Organization. Laboratory testing for coronavirus disease
383 2019 (COVID-19) in suspected human cases: interim guidance, World
384 Health Organization, 2 March, 2020.
- 385 [26] Nowak, M. A., May, R. M., (2000). *Virus Dynamics: Mathematics*
386 *Principles of Immunology and Virology*, Oxford University Press, Lon-
387 don, UK.
- 388 [27] Perelson, A. S., Nelson, P. W., (1999) *Mathematical analysis of HIV-1*
389 *dynamics in vivo*, *SIAM Review*, vol. 41, no. 1, pp. 344.
- 390 [28] Chatterjee, A. N., Saha, S., Roy, P. K., (2015), *Human immunodeficiency*
391 *virus/acquired immune deficiency syndrome: Using drug from*
392 *mathematical perspective*, *World J Virol*, 4(4): 356-364.
- 393 [29] Roy, P. K., Chatterjee, A. N., Greenhalgh, D., Khan, Q. J.A., (2013),
394 *Long Term Dynamics in a Mathematical Model of HIV-1 infection with*
395 *delay in Different Variants of the basic drug the basic drug therapy*,
396 *Nonlinear Analysis: Real World Applications*, 14, pp.1621–1633.
- 397 [30] Wu, C., Liu, Y., Yang, Y. et al. (2020). Analysis of therapeutic targets
398 for SARS-CoV-2 and discovery of potential drugs by computational
399 methods. *Acta Pharmaceutica Sinica B*.
- 400 [31] Puggioni, F., Alves-Correia, M., Mohamed, M. F. et al. (2019). Im-
401 munostimulants in respiratory diseases: focus on Pidotimod. *Multidis-*
402 *ciplinary Respiratory Medicine*, 14(1), 1–10.
- 403 [32] Qureshi, S., Yusuf, A. Fractional derivatives applied to MSEIR prob-
404 lems: Comparative study with real world data. *Eur. Phys. J. Plus* 134,
405 171 (2019). <https://doi.org/10.1140/epjp/i2019-12661-7>

406 [33] Sania Qureshi, Abdullahi Yusuf, Asif Ali Shaikh, Mustafa, Transmission
 407 dynamics of varicella zoster virus modeled by classical and novel frac-
 408 tional operators using real statistical data, Physica A 534 (2019) 122149
 409

410 **Appendix-A**

$$\begin{aligned}
 A_1 &= -(a_{11} + a_{22} + a_{33} + a_{44} + a_{55}), \\
 A_2 &= a_{11}(a_{22} + a_{33}) + a_{23}a_{32} + a_{22}a_{33} - a_{14}a_{41} + (a_{11} + a_{22} + a_{33})a_{44} \\
 &\quad - a_{25}a_{52} + (a_{11} + a_{22} + a_{33} + a_{44})a_{55}, \\
 A_3 &= a_{32}(a_{11}a_{23} - a_{13}a_{21} - a_{24}a_{43}) - a_{11}a_{22}(a_{44} + a_{33}) + a_{14}a_{33}a_{41} \\
 &\quad + a_{44}(a_{23}a_{32} - a_{11}a_{33} - a_{22}a_{33}) + a_{25}a_{52}(a_{33} + a_{44} + a_{11}) \\
 &\quad - a_{11}a_{55}(a_{22} + a_{33}) + a_{23}a_{32}a_{55} - a_{22}a_{33}a_{55} \\
 &\quad - a_{44}a_{55}(a_{11} + a_{14}a_{41}a_{55} + a_{22} + a_{33}) + a_{14}a_{22}a_{41}, \\
 A_4 &= a_{32}a_{41}(a_{23}a_{14} - a_{13}a_{24}) - a_{22}a_{33}(a_{14}a_{41} - a_{44}a_{55}) \\
 &\quad - a_{14}a_{21}a_{32}a_{43} + a_{13}a_{21}a_{32}a_{44} - a_{11}(a_{23}a_{32}a_{44} + a_{25}a_{33}a_{52}) \\
 &\quad + a_{52}(a_{14}a_{25}a_{41} - a_{11}a_{25}a_{44} - a_{25}a_{33}a_{44}) + a_{13}a_{21}a_{32}a_{55} \\
 &\quad - a_{11}a_{55}(a_{23}a_{32} - a_{22}a_{33}) - a_{41}a_{55}(a_{14}a_{22} + a_{14}a_{33}) \\
 &\quad + a_{55}(a_{24}a_{32}a_{43} + a_{11}a_{22}a_{44} - a_{23}a_{32}a_{44}) \\
 &\quad + a_{11}a_{33}(a_{22}a_{44} + a_{44}a_{55}) + a_{11}a_{24}a_{32}a_{43}, \\
 A_5 &= a_{25}a_{33}(a_{11}a_{44}a_{52} - a_{14}a_{41}a_{52}) + (a_{14}a_{21}a_{32} - a_{11}a_{24}a_{32})a_{43}a_{55} \\
 &\quad + a_{41}a_{55}(a_{13}a_{24}a_{32} - a_{14}a_{23}a_{32} + a_{14}a_{22}a_{33}) + a_{44}a_{55}(a_{11}a_{23}a_{32} \\
 &\quad - a_{13}a_{21}a_{32} - a_{11}a_{22}a_{33}).
 \end{aligned}$$

411 **Appendix-B**

$$\begin{aligned}
 B_1 &= -(b_{11} + b_{22} + b_{33} + b_{44}), \\
 B_2 &= b_{11}b_{22} - b_{23}b_{32} + b_{33}(b_{11} + b_{22}) - b_{14}b_{41} \\
 &\quad + b_{44}(b_{11} + b_{22} + b_{33}) \\
 B_3 &= b_{32}(b_{11}b_{23} - b_{13}b_{21}) - b_{22}(b_{11}b_{33} - b_{14}b_{41}) \\
 &\quad + b_{14}b_{33}b_{41} - b_{24}b_{32}b_{43} \\
 &\quad + (b_{23}b_{32} - b_{11}b_{22})b_{44} - b_{33}b_{44}(b_{11} + b_{22}), \\
 B_4 &= b_{14}b_{41}(b_{23}b_{32} - b_{22}b_{33}) - b_{13}b_{24}b_{32}b_{41} \\
 &\quad - b_{14}b_{21}b_{32}b_{43} + b_{32}(b_{11}b_{24}b_{43} + b_{13}b_{21}b_{44}) \\
 &\quad - b_{44}b_{11}(b_{23}b_{32} - b_{22}b_{33}).
 \end{aligned}$$